- Home
- IMTX
IMTX
Immatics N.V.
as 12-18-2024 9:52am EST
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
| Founded: | N/A | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 954.2M | IPO Year: | N/A |
| Target Price: | $16.67 | AVG Volume (30 days): | 522.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.99 - $13.77 | Next Earning Date: | 11-18-2024 |
| Revenue: | $128,824,447 | Revenue Growth: | 52.53% |
| Revenue Growth (this year): | 90.79% | Revenue Growth (next year): | -39.49% |
Latest Immatics N.V. News
IMTX Breaking Stock News: Dive into IMTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
TipRanks
a month ago
Immatics Sees Revenue Surge Despite R&D Expenses
GlobeNewswire
a month ago
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
GlobeNewswire
a month ago
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Simply Wall St.
2 months ago
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50%
TipRanks
2 months ago
Immatics Advances IMA203 to Phase 3 Trial in Melanoma
GlobeNewswire
2 months ago
Immatics Announces Pricing of $150 Million Public Offering
GlobeNewswire
2 months ago
Immatics Announces Proposed $150 Million Public Offering
Compare IMTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMTX Immatics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.